Sabra Healthcare REIT, Inc. (NASDAQ:SBRA – Get Free Report) CEO Richard Matros sold 200,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $20.83, for a total value of $4,166,000.00. Following the completion of the sale, the chief executive officer directly owned 1,657,686 shares of the company’s stock, valued at $34,529,599.38. The trade was a 10.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sabra Healthcare REIT Trading Down 0.1%
Shares of NASDAQ:SBRA opened at $20.79 on Thursday. The business’s 50-day moving average is $20.68 and its 200 day moving average is $20.20. Sabra Healthcare REIT, Inc. has a 1 year low of $17.17 and a 1 year high of $22.77. The firm has a market capitalization of $5.31 billion, a P/E ratio of 79.96, a P/E/G ratio of 1.58 and a beta of 0.65. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.07 and a quick ratio of 3.07.
Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The real estate investment trust reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.27). The business had revenue of $230.11 million during the quarter, compared to analysts’ expectations of $219.39 million. Sabra Healthcare REIT had a net margin of 7.61% and a return on equity of 2.34%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.38 earnings per share. On average, research analysts predict that Sabra Healthcare REIT, Inc. will post 1.52 earnings per share for the current fiscal year.
Sabra Healthcare REIT Dividend Announcement
Institutional Investors Weigh In On Sabra Healthcare REIT
A number of large investors have recently bought and sold shares of the company. Rothschild Investment LLC raised its position in Sabra Healthcare REIT by 164.6% during the 4th quarter. Rothschild Investment LLC now owns 1,429 shares of the real estate investment trust’s stock worth $27,000 after buying an additional 889 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Sabra Healthcare REIT by 97.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the real estate investment trust’s stock valued at $27,000 after acquiring an additional 714 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Sabra Healthcare REIT by 70.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,465 shares of the real estate investment trust’s stock valued at $29,000 after acquiring an additional 603 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Sabra Healthcare REIT in the third quarter worth $30,000. Finally, Larson Financial Group LLC increased its stake in shares of Sabra Healthcare REIT by 42.3% in the third quarter. Larson Financial Group LLC now owns 1,860 shares of the real estate investment trust’s stock worth $35,000 after acquiring an additional 553 shares during the period. Hedge funds and other institutional investors own 99.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on SBRA. Citigroup reissued a “market outperform” rating on shares of Sabra Healthcare REIT in a research report on Wednesday, July 22nd. Truist Financial raised their price target on shares of Sabra Healthcare REIT from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Scotiabank lowered their price objective on shares of Sabra Healthcare REIT from $22.00 to $19.00 and set a “sector perform” rating for the company in a research note on Thursday, June 18th. Citizens Jmp boosted their price objective on shares of Sabra Healthcare REIT from $23.00 to $25.00 and gave the company a “market outperform” rating in a report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sabra Healthcare REIT in a report on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $22.17.
View Our Latest Analysis on Sabra Healthcare REIT
Sabra Healthcare REIT Company Profile
Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.
Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.
Featured Stories
- Five stocks we like better than Sabra Healthcare REIT
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Sabra Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
